LFST LifeStance Health Group, Inc.

LifeStance Health Group (LFST) has drawn fresh attention after recent trading left the share price at $11.84, with performance over the past week and month moving in different directions. Short term momentum for LifeStance Health Group has cooled, with a 7 day share price return of down 6.6% and a 30 day share price return of down 3.8%. However, the year to date share price return of 70.1% and 1 year total shareholder return of 118.5% still signal a sharp re-rating as investors reassess both...

Despite the sale, the insider still holds 205,000 shares worth $2.6 million.

The past six months have been a windfall for LifeStance Health Group’s shareholders. The company’s stock price has jumped 92.6%, hitting $12.58 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at LifeStance Health Group (NASDAQ:LFST) and its peers.

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LifeStance Health, Tutor Perini, News Corp., Everus Construction and HF Sinclair offer growth potential amid oil and inflation worries.

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.

LifeStance Health Group (LFST) has drawn fresh investor attention after recent trading data showed the stock up over the past month and past 3 months. This move is prompting closer scrutiny of its mental health services business. At a share price of $12.73, LifeStance Health Group has posted a 30 day share price return of 22.76% and a 90 day share price return of 71.79%. The 1 year total shareholder return of 137.06% points to strong recent momentum building from a lower multi year...

LifeStance Health Group has delivered a very strong share price gain over the past year, while its valuation checks send mixed signals. The intrinsic value estimate from a Discounted Cash Flow (DCF) approach points to some upside, yet market multiples suggest the stock screens as expensive and the broader value score is low. Over the past year, LifeStance Health Group has returned about 137%, which puts extra focus on whether recent optimism already prices in much of the story. The long term...

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.

An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LifeStance Health, NVIDIA, Valero, Comfort and National Vision have been highlighted in this Screen of The Week article.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

LifeStance Health posted a quarter that surpassed market expectations, driven primarily by strong clinician productivity and expansion in specialty services. Management credited the company’s ability to grow its clinician base and the adoption of digital workflow tools for the robust performance. CEO David Bourdon highlighted, “We continue to grow our clinician base now at over 8,500 clinicians as our value proposition continues to resonate.” The quarter benefited from improved operational effic

Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Low-leverage stocks like LifeStance Health, Tutor Perini, Valero Energy, SharkNinja and Lumentum offer resilience amid oil and geopolitical risks.

In early August 2026, LifeStance Health Group reported second-quarter results showing higher sales and a move to net profitability, raised its 2026 revenue outlook, and completed a US$97.19 million share repurchase while authorizing a new buyback program of up to US$100 million. Together with new guidance for third-quarter revenue and an expanded focus on clinician productivity and specialty services, these actions signal management’s emphasis on scaling operations while returning capital to...

High oil prices and market volatility spotlight five low-leverage stocks with strong earnings growth and resilient balance sheets.

LifeStance Health (LFST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Behavioral health company LifeStance Health (NASDAQ:LFST) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 26.1% year on year to $435.4 million. Guidance for next quarter’s revenue was optimistic at $430 million at the midpoint, 2.9% above analysts’ estimates. Its non-GAAP profit of $0.11 per share was 32.4% above analysts’ consensus estimates.

Revenue surged 26% as clinician productivity climbed and payer rates improved.

LifeStance Health Group Inc (LFST) delivers exceptional Q2 2026 results with record free cash flow and strategic investments in technology and specialty services.

Moby summary of LifeStance Health Group, Inc.'s Q2 2026 earnings call

LifeStance Health Group (NASDAQ:LFST) reported second-quarter results that exceeded its prior expectations, driven by higher visit volumes, increased revenue per visit and continued clinician productivity gains. The outpatient mental health provider raised its full-year revenue, Center Margin and ad

LifeStance Health (LFST) delivered earnings and revenue surprises of +100.00% and +5.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Behavioral health company LifeStance Health (NASDAQ:LFST) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 26.1% year on year to $435.4 million. Guidance for next quarter’s revenue was optimistic at $430 million at the midpoint, 2.9% above analysts’ estimates. Its GAAP profit of $0.06 per share was $0.03 above analysts’ consensus estimates.

Q1 earnings beat and guidance update put LifeStance Health Group in focus LifeStance Health Group (LFST) drew investor attention after reporting Q1 results that exceeded analyst revenue expectations, alongside higher net income and Adjusted EBITDA, while issuing full year guidance that management said surpassed expectations. See our latest analysis for LifeStance Health Group. Despite the latest Q1 beat, LifeStance Health Group’s share price has eased in the very short term, with the 1 day...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at LifeStance Health Group (NASDAQ:LFST) and its peers.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.